공고 • May 27
Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million. Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.791 million.
Security Name: Odinary Shares
Security Type: Common Stock
Securities Offered: 7,910,000
Price\Range: AUD 0.1
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공고 • May 22
Vectus Biosystems Limited has filed a Follow-on Equity Offering. Vectus Biosystems Limited has filed a Follow-on Equity Offering.
Security Name: Odinary Shares
Security Type: Common Stock
Transaction Features: Subsequent Direct Listing 공고 • Oct 09
Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025 Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025. Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.033 loss per share (vs AU$0.044 loss in FY 2024) Full year 2025 results: AU$0.033 loss per share (improved from AU$0.044 loss in FY 2024). Revenue: AU$478.2k (down 58% from FY 2024). Net loss: AU$1.78m (loss narrowed 24% from FY 2024). Board Change • Aug 18
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Dec 20
Vectus Biosystems Limited Appoints Linda Ann Walters as Non-Executive Director of the Board Vectus Biosystems Limited announced the appointment of Linda Ann Walters as a non-executive director of the board of the company, effective from 20 December 2024. Linda Walters has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. Linda has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization programme. Her expertise spans the fields of human resources, finance, information technology and the commercialization of IP. Linda has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus' operational and commercial capabilities. 공고 • Oct 08
Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024 Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024. Reported Earnings • Oct 05
Full year 2024 earnings released: AU$0.044 loss per share (vs AU$0.072 loss in FY 2023) Full year 2024 results: AU$0.044 loss per share (improved from AU$0.072 loss in FY 2023). Revenue: AU$1.14m (down 16% from FY 2023). Net loss: AU$2.34m (loss narrowed 32% from FY 2023). Products in clinical trials Phase I: 1 Board Change • Oct 01
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 23
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Mar 21
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공고 • Oct 05
Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023 Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023, at 15:00 AUS Eastern Standard Time. Board Change • Sep 25
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. New Risk • Aug 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Earnings have declined by 13% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.2m). Market cap is less than US$100m (AU$21.3m market cap, or US$13.6m). Board Change • Aug 17
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jul 11
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 18
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 21
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Mar 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jan 30
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jan 06
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Dec 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.